In recent years, remarkable progress has been achieved in the field of cancer immunotherapy, particularly through the development and application of immunotherapeutic agents that primarily focus on the CTLA-4, PD-1, and PD-L1 immune checkpoint pathways [37]. This evidence concerns the gene CD274 and cancer.